pmc logo image
Logo of mbdrugsJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
Journal List > Met Based Drugs > v.4(6); 1997

Formats:
Met Based Drugs. 1997; 4(6): 333–338.
doi: 10.1155/MBD.1997.333.
PMCID: PMC2365087
Copyright © 1997 Hindawi Publishing Corporation.
Rh2(CF3CONH)4: The First Biological Assays of a Rhodium (II) Amidate
Breno Pannia Espósito,corresponding author1 Szulim Ber Zyngier,2 Aparecido Ribeiro de Souza,3 and Renato Najjar1
1 Institute of Chemistry, University of São Paulo, Av. Lineu Prestes 748, São Paulo, 05508-900, Brazil,
2 Institute of Biomedical Sciences - I, University of São Paulo, Av. Lineu Prestes 1524, São Paulo, 05508-900, Brazil,
3 Institute of Chemistry, Federal University of Goiás, Campus II, P.O. Box 131, Goiânia, 74001-970, Brazil,
Breno Pannia Espósito, Email: bpesposi/at/quim.iq.usp.br.
corresponding authorCorresponding author.
Received October 20, 1997; Accepted December 3, 1997.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The rhodium (II) complexes Rh2(tfa)4.2(tfac) and Rh2(tfacam)4 (tfacam = CF3CONH-,tfa = CF3COO-,tfac = CF3CONH2) were synthesized and characterized by microanalysis and electronic and vibrational spectroscopies. Rh2(tfacam)4 was tested both in vitro (U937 and K562 human leukemia cells and Ehrlich ascitic tumor cells) and in vivo for cytostatic activity and lethal dose determination, respectively. This is the first rhodium tetra-amidate to have its biological activity evaluated. The LD50 value for Rh2(tfacam)4 is of the same order as that of cisplatin, and it was verified that the rhodium complex usually needs lower doses than cisplatin to promote the same inhibitory effects.
Articles from Metal-Based Drugs are provided here courtesy of
Hindawi Publishing Corporation

PubMed articles by these authors

Links